BACE1 and Alzheimer disease: Such a partial BACE1 inhibition therapeutic approach is supported by the previous finding of McConlogue et al. [38] that indicated, at least in a mouse model of AD, that only a 12 % decrease in Aβ levels in brain results in dramatic reduction in plaque pathology.